What is Putney?
Putney operates as a specialized pharmaceutical entity dedicated to the development and distribution of high-quality, cost-effective generic medications for pets. By bridging the gap between affordability and clinical efficacy, the company empowers veterinary professionals to enhance treatment compliance and improve patient outcomes. Putney's market position is defined by its commitment to research and development, ensuring a robust pipeline of generic veterinary products that address the evolving needs of companion animal health. Through strategic partnerships and a focus on supply chain reliability, the firm has established itself as a critical resource for veterinarians and pet owners alike, effectively lowering the barrier to entry for essential medical care.
How much funding has Putney raised?
Putney has raised a total of $49.3M across 5 funding rounds:
Series A
$2.5M
Series B
$6.7M
Series C
$21M
Debt
$3M
Private Equity
$16.1M
Series A (2007): $2.5M, investors not publicly disclosed
Series B (2009): $6.7M, investors not publicly disclosed
Series C (2011): $21M supported by NewSpring Capital and Safeguard Scientifics
Debt (2014): $3M featuring NewSpring Health Capital
Private Equity (2014): $16.1M, investors not publicly disclosed
Key Investors in Putney
NewSpring Capital
NewSpring partners with companies in dynamic industries to catalyze new growth. Partnering with management teams to help develop their businesses into market leaders, NewSpring identifies opportunities and builds relationships using through it's network of industry leaders.
Safeguard Scientifics
Safeguard Scientifics is a venture capital and private equity company. It provides capital and relevant expertise to fuel the growth of technology-driven businesses in healthcare, financial services and digital media.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Putney?
With the recent major strategic investment, Putney is well-positioned to accelerate its research and development initiatives, focusing on the next generation of generic veterinary therapeutics. The company's growth strategy likely involves expanding its product portfolio to address a broader range of companion animal conditions, thereby increasing its market share in the veterinary pharmaceutical space. By leveraging its established network and industry expertise, Putney aims to further optimize its operational efficiency and solidify its reputation as a leader in affordable veterinary medicine. Future milestones will likely center on scaling production capabilities and deepening its penetration into key veterinary markets, ensuring sustained value creation for its stakeholders and improved health outcomes for pets.
See full Putney company page
